Extension Study Evaluating Etanercept in Ankylosing Spondylitis

This study has been completed.

Sponsor:

Information provided by:

Wyeth is now a wholly owned subsidiary of Pfizer

ClinicalTrials.gov Identifier:

NCT00410046

First received: December 8, 2006

Last updated: April 9, 2012

Last verified: April 2012

History of Changes

Results First Received: October 30, 2009

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Efficacy Study; Intervention Model: Single Group Assignment; Masking: Open Label; Primary Purpose: Treatment
Condition:	Ankylosing Spondylitis
Intervention:	Drug: Enbrel (etanercept)

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients were recruited in Europe from November 2006 to January 2008.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Patients in 0881A3-402 (NCT00247962) were randomized to receive etanercept (ETN) or sulphasalazine (SSZ). After completion, they were eligible for enrollment into this extension study and all patients received ETN. Outcome measure analysis kept the 0881A3-402 assignment of ETN or SSZ. This enabled an analysis of changes from the original baseline.

Reporting Groups

	Description
Etanercept	Patients received ETN dose 50 mg once weekly or Sulphasalazine dose 3 g daily in study 0881A3-402 for 16 weeks. Upon enrollment into this study, all received subcutaneous injections of etanercept 50 mg once weekly for 36 weeks.

Participant Flow: Overall Study

	Etanercept
STARTED	84
COMPLETED	79
NOT COMPLETED	5
Adverse Event	3
Withdrawal by Subject	1
Lost to Follow-up	1

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Etanercept	Patients received ETN dose 50 mg once weekly or Sulphasalazine dose 3 g daily in study 0881A3-402 for 16 weeks. Upon enrollment into this study, all received subcutaneous injections of etanercept 50 mg once weekly for 36 weeks.

Baseline Measures

	Etanercept
Number of Participants [units: participants]	84
Age [units: years] Mean ± Standard Deviation	42.70 ± 10.49
Gender [units: patients]
Female	13
Male	71

Outcome Measures

Show All Outcome Measures

1. Primary:

Number of Patients Using Healthcare Resources in the 48 Weeks Before and During Treatment [ Time Frame: 96 weeks ]

Show Outcome Measure 1

2. Primary:

Number of Patients Taking Sick Leave in the 48 Weeks Before and During Treatment [ Time Frame: 96 weeks ]

Show Outcome Measure 2

3. Secondary:

Number of Patients Utilizing Healthcare Resources During 48 Weeks of Treatment [ Time Frame: 48 weeks ]

Show Outcome Measure 3

4. Secondary:

Number of Times Healthcare Resources Were Used Per Patient During 48 Weeks of Treatment [ Time Frame: 48 weeks ]

Show Outcome Measure 4

5. Secondary:

Number of Patients With Sick Leave During 48 Weeks Treatment [ Time Frame: 48 weeks ]

Hide Outcome Measure 5

Measure Type	Secondary
Measure Title	Number of Patients With Sick Leave During 48 Weeks Treatment
Measure Description	The impact of treatment on work productivity was assessed by sick leave. Patients were asked whether or not they had taken sick leave during the 48 weeks of treatment, and if so, how many days.
Time Frame	48 weeks
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All patients who completed study 0881A3-402 (NCT00247962), continued into this study, received at least 1 dose of study drug and had at least 1 post-baseline assessment.

Reporting Groups

	Description
Etanercept / ETN	Patients received ETN dose 50 mg once weekly in study 0881A3-402 for 16 weeks. Upon enrollment into study 405, all received subcutaneous injections of etanercept 50 mg once weekly for 36 weeks.
SSZ / ETN	Patients received Sulphasalazine dose 3 g daily in study 0881A3-402 for 16 weeks. Upon enrollment into study 405, all received subcutaneous injections of etanercept 50 mg once weekly for 36 weeks.

Measured Values

	Etanercept / ETN	SSZ / ETN
Number of Participants Analyzed [units: participants]	59	25
Number of Patients With Sick Leave During 48 Weeks Treatment [units: patients]
Patients employed during the study	45	13
Patients with sick leave during the past 12 months	23	10

Statistical Analysis 1 for Number of Patients With Sick Leave During 48 Weeks Treatment

Groups ^[1]	All groups
Method ^[2]	Fisher Exact
P Value ^[3]	1.00

[1]	Additional details about the analysis, such as null hypothesis and power calculation:
	Analysis completed for patients with sick leave during the past 12 months
[2]	Other relevant information, such as adjustments or degrees of freedom:
	No text entered.
[3]	Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
	No text entered.

6. Secondary:

Number of Sick Days Per Patient During the 48 Weeks of Treatment [ Time Frame: 48 weeks ]

Show Outcome Measure 6

7. Secondary:

Change in Patient Global Assessment of Disease Activity From Baseline to Week 38 [ Time Frame: Baseline and 38 weeks ]

Show Outcome Measure 7

8. Secondary:

Change in Total Back Pain Score From Baseline to Week 38 [ Time Frame: Baseline and 38 weeks ]

Show Outcome Measure 8

9. Secondary:

Change in Bath Ankylosing Spondylitis Functional Index (BASFI) Score From Baseline to Week 38 [ Time Frame: Baseline and 38 weeks ]

Show Outcome Measure 9

10. Secondary:

Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score From Baseline to Week 38 [ Time Frame: Baseline and 38 weeks ]

Show Outcome Measure 10

11. Secondary:

Change in Bath Ankylosing Spondylitis Metrology Index (BASMI) Score From Baseline to Weeks 38 [ Time Frame: Baseline and 38 weeks ]

Show Outcome Measure 11

12. Secondary:

Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score for Fatigue From Baseline to Week 38 [ Time Frame: Baseline and 38 weeks ]

Show Outcome Measure 12

13. Secondary:

Change in Baseline Ankylosing Spondylitis Quality of Life (ASQoL) Score From Baseline to Week 38 [ Time Frame: Baseline and 38 weeks ]

Show Outcome Measure 13

14. Secondary:

Change From Baseline Haywood Quality of Life Score From Baseline to Week 38 [ Time Frame: Baseline and 38 weeks ]

Show Outcome Measure 14

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: U. S. Contact Center
Organization: Wyeth
e-mail: clintrialresults@wyeth.com

No publications provided

Responsible Party:	Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
ClinicalTrials.gov Identifier:	NCT00410046 History of Changes
Other Study ID Numbers:	0881A3-405
Study First Received:	December 8, 2006
Results First Received:	October 30, 2009
Last Updated:	April 9, 2012
Health Authority:	Denmark: National Board of Health

To Top